Effect of different variants of radiation treatment on the parameters of tissue plasminogen activator and its inhibitor in the blood of patients with metastatic brain lesions
Authors:
- Irina A. GoroshinskayaIGIrina A. Goroshinskaya
- Artem A. BabasinovABArtem A. Babasinov
- Irina V. KaplievaIKIrina V. Kaplieva
- Eduard E. RostorguevEREduard E. Rostorguev
- Stanislav G. VlasovSVStanislav G. Vlasov
- Olga G. RodionovaOROlga G. Rodionova
- Polina S. KachesovaPKPolina S. Kachesova
- Lidia K. TrepitakiLTLidia K. Trepitaki
Open Access
- 10 April 2026
- journal article
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (2) , 119-124
Abstract
Background. The prevalence of metastatic brain tumors (MBT), accompanied by high mortality and limited treatment options associated with the localization of the process, underscores the importance of studying the metabolic systems involved in the progression of malignant disease and sensitivity to antitumor treatment. One such system is the fibrinolytic system, which comprises a series of activators, inhibitors, and receptors. Aim. To examine the levels and activities of tissue plasminogen activator (tPA), as well as fibrinolysis inhibitor, in the blood of patients with MBT who are undergoing various radiotherapeutic treatments. Materials and methods. The activity and content of tPA and type 1 plasminogen activator inhibitor (PAI-1) were studied in the blood plasma of 38 patients with MBT by enzyme-linked immunosorbent assay. The results were compared with the data of 18 people without oncologic pathology (donor group). Three groups were formed according to the treatment options: Control group – stereotactic radiotherapy on the place of the removed metastasis with a single focal dose (SFD) of 6 Gy up to a total dose of 30 Gy; Main group No. 1 – after a session of preoperative radiosurgery with a SFD of 10–15 Gy, the metastatic focus was removed 24 hours later; Main group No. 2 – staged radiosurgery (SRS) was performed in 3 stages with a SFD of 10 Gy and an interval between sessions of 14 days (total 30 Gy). Results. For patients with metastatic brain lesions, before the start of treatment, a 2.1-fold increase in tPA activity was typical, with a 3.6-fold decrease in its content, leading to a 10-fold increase in their ratio. In the control group, tPA activity remained elevated 3 days after surgery, after a month it did not differ from the level in donors, and the tPA content was reduced. In both main groups, a heightened level of tPA activity was observed throughout the observation period. After one month, this activity was found to be 2.6 times higher compared to the control group (p≤0.001). Only patients receiving SRS were characterized by an increase in the initially decreased tPA content, accompanied by a shift towards normalization of the ratio of tPA activity to its content. This was concomitant with an increase in PAI-1 activity, reaching the donor level. Conclusion. The identified dynamics of tPA parameters may contribute to the clinical efficacy of SRS.Keywords
This publication has 17 references indexed in Scilit:
- Indicators of the fibrinolytic system in the blood and cerebrospinal fluid of patients with metastatic brain lesionsHead and Neck Tumors (HNT), 2025
- Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysisRadiation Oncology, 2024
- Post-Translational Oxidative Modifications of Hemostasis Proteins: Structure, Function, and RegulationBiochemistry (Moscow), 2024
- Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directionsNeuro-Oncology, 2022
- Metabolism in the progression and metastasis of brain tumorsCancer Letters, 2022
- Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancerJournal of Cancer Research and Clinical Oncology, 2020
- Urokinase-Type Plasminogen Activator System in Norm and in Life-Threatening Processes (Review)General Reanimatology, 2018
- DYNAMICS OF THE TISSUE SYSTEM OF PLASMINOGEN REGULATORS IN CUTANEOUS MELANOMA WITH CHRONIC PAIN IN FEMALE MICETranslational Medicine, 2018
- RESULTS OF RADIOSURGICAL AND DRUG TREATMENT OF PATIENTS WITH BRAIN METASTASESHead and Neck Tumors (HNT), 2017
- Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic TestingCancer Research, 2015